Sitagliptin HCL monohydrate

Sitagliptin HCL monohydrate is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.

1.1 Treatment of Type 2 Diabetes Mellitus

Sitagliptin HCl monohydrate is a first-in-class DPP-4 inhibitor used to:

Improve glycemic control in adults with type 2 diabetes mellitus (T2DM)

Be prescribed alone or in combination with other antidiabetic agents like:

Metformin

Sulfonylureas

Thiazolidinediones (e.g., pioglitazone)

Insulin

It is not used for type 1 diabetes or diabetic ketoacidosis.

1.2 Oral Antidiabetic Agent

Unlike insulin or injectable GLP-1 analogs, sitagliptin is orally bioavailable and suitable for:

Outpatient long-term use

Patients who prefer oral tablets over injections

1.3 Fixed-Dose Combination Products

Sitagliptin is often formulated in fixed-dose combinations such as:

Sitagliptin + Metformin (brand name: Janumet®)

These combinations simplify therapy and improve patient compliance.

1.4 Investigational and Adjunctive Use

Ongoing research investigates sitagliptin for potential benefits in:

Cardiovascular protection

Weight management

β-cell preservation

Inflammatory modulation in metabolic syndrome

2.1 DPP-4 Inhibition Mechanism

Sitagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which:

Increases levels of incretin hormones (GLP-1 and GIP)

Enhances glucose-dependent insulin secretion

Suppresses glucagon release

Helps lower postprandial and fasting blood glucose

2.2 Weight-Neutral and Low Hypoglycemia Risk

Unlike sulfonylureas or insulin:

Sitagliptin is weight neutral

Has a low risk of hypoglycemia, especially when not used with sulfonylureas or insulin

2.3 Once-Daily Dosing

It has a long half-life (~12.4 hours), allowing once-daily dosing, which:

Enhances patient convenience

Improves adherence to treatment

2.4 Renal Safety and Dosage Adjustment

While sitagliptin is primarily renally excreted, it is generally well tolerated in patients with mild to moderate renal impairment, with appropriate dose adjustments.

2.5 Well-Tolerated with Mild Side Effects

Common side effects are mild and may include:

Nasopharyngitis

Headache

Upper respiratory tract infections

Rare but serious adverse effects (e.g., pancreatitis, hypersensitivity reactions) are infrequent with proper patient monitoring.

Sitagliptin HCl monohydrate (CAS 862156-92-1) is a cornerstone in the modern management of type 2 diabetes mellitus due to its targeted mechanism, patient-friendly oral administration, and favorable safety profile. By enhancing the body's natural incretin system through DPP-4 inhibition, sitagliptin helps regulate glucose levels without causing significant hypoglycemia or weight gain. Its integration into combination therapies and fixed-dose regimens further strengthens its role in personalized diabetes care. With growing research into its extended benefits beyond glucose control, sitagliptin continues to be a vital tool in combating the global burden of type 2 diabetes.

Previous

Iopromide丨CAS 73334-07-3

Next

Clarithromycin丨CAS 81103-11-9